Heart Outcomes Prevention Evaluation-3

Trial Profile

Heart Outcomes Prevention Evaluation-3

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Candesartan cilexetil/hydrochlorothiazide (Primary) ; Rosuvastatin (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms HOPE-3
  • Most Recent Events

    • 19 Jul 2016 Results published in the Annals of Internal Medicine
    • 13 Jun 2016 Trial design presented at 26th European Meeting on Hypertension and Cardiovascular Protection.
    • 02 Apr 2016 Results of cholesterol lowering in intermediate-risk persons published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top